20
Participants
Start Date
May 15, 2019
Primary Completion Date
December 22, 2021
Study Completion Date
October 24, 2023
Atezolizumab
"* 1200mg IV on day1 before start of cycle 'atezolizuamb, bevacizumab + FOLFOX(Oxaliplatin, Levoleucovorin, 5-FU')~* 840mg IV D1 of C1-12 (Cycle: every 2 weeks)"
Bevacizumab
5mg/kg IV D1 of C1-12 (Cycle: every 2 weeks) at least 5 minutes after completion of atezolizumab
Oxaliplatin
85mg/m2 IV D1 of C1-12 (Cycle: every 2 weeks)
Levoleucovorin
200mg/m2 IV D1 of C1-12 (Cycle: every 2 weeks)
5-FU
"* 5-FU Bolus: 400mg/m2 IV bolus D1 of C1-12 (Cycle: every 2 weeks)~* 5-FU infusion: 2400mg/mg continuous IV infusion over 46hours D1-3 of C1-12 (Cycle: every 2 weeks)"
Asan Medical Center, Seoul
Lead Sponsor
Hoffmann-La Roche
INDUSTRY
Asan Medical Center
OTHER